Originally published by our sister publication Gastroenterology & Endoscopy News
By Marcus A. Banks
WASHINGTON—Apraglutide, a synthetic glucagon-like peptide-2 analog taken subcutaneously weekly, reduces the need for parenteral nutrition in people with intestinal failure due to short bowel syndrome, according to the first results of the phase 3 STARS trial presented at DDW 2024.
“First and above all, GLP-2 analogs are great at reducing the need for parenteral support. But at the